BRCA Gene Mutations in Cancer

SEP 8, 2026 · JOURNAL ARTICLE

Prognostic and therapeutic implications of BRCA1 and BRCA2 mutations in ovarian cancer

Frontiers in Oncology

A literature review synthesizing evidence on BRCA1/2 as prognostic and predictive biomarkers in ovarian cancer, providing clinical recommendations for testing and treatment selection rather than reporting original trial data.

SEP 4, 2026 · JOURNAL ARTICLE

Applications of Olaparib and Durvalumab Combination Therapy for a Founder BRCA1 Mutation in the Chinese Han Population: A Literature Review

Scholarly Review .

A literature review synthesizing current evidence on PARP inhibitor and immunotherapy combinations for BRCA-mutated cancers, offering clinical perspective rather than reporting original trial data.

SEP 1, 2026 · JOURNAL ARTICLE

Brca1 heterozygosity leads to hepatic steatosis in male and female mice despite sexually dimorphic effects on systemic metabolism

Metabolism

A well-designed preclinical study with mechanistic depth and human genetic support, but limited to mouse models and surrogate endpoints; findings require clinical validation.

AUG 18, 2026 · JOURNAL ARTICLE

The Assessment of Race, the 21-Gene Recurrence Score, and Breast Cancer Outcomes at Kaiser Permanente

Cancers

A retrospective cohort study of adequate size reporting statistically significant mortality differences by race and Oncotype DX score, but with limited scope (single health system) and inconsistent significance across score categories, requiring confirmation in diverse populations.

AUG 17, 2026 · JOURNAL ARTICLE

Multidisciplinary Management Considerations in Invasive Lobular Breast Cancer: It Isn’t Just Ductal

Annals of Surgical Oncology

Expert consensus panel review synthesizing literature on disease-specific management of invasive lobular carcinoma, providing multidisciplinary recommendations without presenting new primary data.

AUG 13, 2026 · JOURNAL ARTICLE

Menopausal Estrogen Therapy and Risk of Breast Cancer

Obstetrics and Gynecology

Meta-analysis of 10 RCTs in 14,282 participants showing estrogen-only therapy reduces breast cancer risk (RR 0.77, 95% CI 0.65–0.91, P=.002), supported by a large matched cohort in BRCA carriers; rigorous design with clear effect but requires hysterectomy and needs confirmatory data in that specific population.

AUG 12, 2026 · JOURNAL ARTICLE

Combination olaparib and cyclophosphamide cancer therapy exacerbates ovarian reserve depletion in mice with conditional loss of Brca1 in oocytes

Frontiers in Endocrinology

Preclinical animal model study raising a novel question about BRCA1 deficiency and ovarian toxicity from combination therapy; does not yet support clinical practice changes.